If you have been reading about 合成肽 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-27. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
On 23 April, Trump announced that Israel and Lebanon agreed to a three-week extension of the ceasefire. On 15 May, the truce was extended by Israel and Lebanon for another 45 days. On 1 June, Israel and Hezbollah agreed to a ceasefire, with Israel committing not to target Beirut's southern suburbs and Hezbollah vowing not to attack Israel, under a US proposal aiming to extend the ceasefire to all of Lebanon. On 3 June, Israel and Lebanon reached an agreement to renew the ceasefire, facilitated by the US, and to create "pilot zones". On 4 June, Hezbollah rejected the previously announced truce deal, demanding instead a comprehensive truce and a full withdrawal of Israel from Lebanon. On 19 June, President Trump announced that Israel and Hezbollah have reached a truce, facilitated by the US, Qatar, and Iran. On 26 June, US Secretary of State Marco Rubio announced a framework deal between Israel and Lebanon for "lasting peace and security" via US mediation. The agreement includes a cease-fire, requiring Hezbollah to end hostilities and withdraw from southern Lebanon, but it was subsequently rejected by Hezbollah.
=== Downblending === The opposite of enriching is downblending. Surplus highly enriched uranium can be downblended with depleted uranium or natural uranium to turn it into low-enriched uranium suitable for use in commercial nuclear fuel. 238U from depleted uranium and natural uranium is also used with recycled 239Pu from nuclear weapons stockpiles for making mixed oxide fuel (MOX), which is now being redirected to become fuel for nuclear reactors. This dilution, also called downblending, means that any nation or group that acquired the finished fuel would have to repeat the very expensive and complex chemical separation of uranium and plutonium process before assembling a weapon.
== Hfe knockout mice == It is possible to delete part or all of a gene of interest in mice (or other experimental animals), as a means of studying the function of the gene and its protein. Such mice are called "knockouts" with respect to the deleted gene. Hfe is the mouse equivalent of the human hemochromatosis gene HFE. The protein encoded by HFE is Hfe. Mice homozygous (two abnormal gene copies) for a targeted knockout of all six transcribed Hfe exons are designated Hfe−/−. Iron-related traits of Hfe−/− mice, including increased iron absorption and hepatic iron loading, are inherited in an autosomal recessive pattern. Thus, the Hfe−/− mouse model simulates important genetic and physiological abnormalities of HFE hemochromatosis. Other knockout mice were created to delete the second and third HFE exons (corresponding to α1 and α2 domains of Hfe). Mice homozygous for this deletion also had increased duodenal iron absorption, elevated plasma iron and transferrin saturation levels, and iron overload, mainly in hepatocytes. Mice have also been created that are homozygous for a missense mutation in Hfe (C282Y). These mice correspond to humans with hemochromatosis who are homozygous for HFE C282Y. These mice develop iron loading that is less severe than that of Hfe−/− mice.
It is almost certain that the Augustus was originally painted, but so few traces remain today (having been lost in the ground and having faded since discovery) that historians have had to fall back on old watercolors and new scientific investigations for evidence. Vincenz Brinkmann of Munich researched the use of color on ancient sculpture in the 1980s using ultraviolet rays to find traces of color. Today, the Vatican Museums have produced a copy of the statue so as to paint it in the theorized original colors, as confirmed when the statue was cleaned in 1999. However, an art historian of the University of St Andrews in Scotland, Fabio Barry, has criticized this reconstitution as unsubtle and exaggerated, while other critics have argued that there are many notable differences between the original Prima Porta of Augustus and the painted recreation. However, due to the ongoing disagreement on the statue's pigmentation there is little information on or exploration of the usage of these colors. Another copy was painted with a different color scheme for the Tarraco Viva 2014 Festival. Since at least the 18th century, the familiar sight of Roman sculptures that lack their original paint has encouraged the idea that monochromy is the natural condition for classical sculpture; but surface treatment is now recognized as integral to the overall effect of the sculpture. The writings of second-century polymath Lucian provide a good example of how color functioned for a work of that time, "I Fear I stand in the way of her most important feature!...
Sources: en.wikipedia.org
During the bidding process, 41 cities with 42 existing, fully functional venues with regular tenants (except Olympic Stadium in Montreal) and two venues then under construction (Allegiant Stadium in Las Vegas and SoFi Stadium in Los Angeles) submitted to be part of the bid: three venues in three cities in Mexico, six venues in six cities in Canada, and 35 venues in 32 cities in the United States. A first-round elimination removed nine venues and nine cities. A second-round elimination cut an additional nine venues in six cities, while three venues in three cities (Soldier Field in Chicago, U.S. Bank Stadium in Minneapolis, and BC Place in Vancouver) dropped out because FIFA was unwilling to negotiate financial details. After Montreal dropped out in July 2021 because it lacked provincial funding and support to renovate Olympic Stadium, Vancouver rejoined the bid as a candidate city in April 2022, bringing the total number to 24 venues, each in its own city or metropolitan area. On June 16, 2022, the sixteen host cities–two in Canada, three in Mexico, and eleven in the United States–were announced by FIFA: Atlanta, Boston, Dallas, Guadalajara, Houston, Kansas City, Los Angeles, Mexico City, Miami, Monterrey, New York/New Jersey, Philadelphia, San Francisco Bay Area, Seattle, Toronto, and Vancouver. Eight of the sixteen chosen stadiums had permanent artificial turf surfaces that were replaced with grass under the direction of FIFA and a University of Tennessee–Michigan State University research team.
== External links == A Conversation with Fred W. McLafferty 2006, 90 minute video, for Cornell University. Center for Oral History. "Fred W. McLafferty". Science History Institute. Grayson, Michael A. (23 January 2007). Fred W. McLafferty, Transcript of Interviews Conducted by Michael A. Grayson at Cornell University Ithaca, New York on 22 and 23 January 2007 (PDF). Philadelphia, PA: Chemical Heritage Foundation.
Ethylestrenol, also known as 3-deketo-17α-ethyl-19-nortestosterone or as 17α-ethylestr-4-en-17β-ol, is a synthetic estrane steroid and a 17α-alkylated derivative of nandrolone (19-nortestosterone; 19-NT). It is specifically the 17α-ethyl and 3-deketo derivative of nandrolone as well as the 3-deketo derivative of norethandrolone (17α-ethyl-19-NT). Other related AAS include bolenol (3-deketo-17α-ethyl-19-nor-5-androstenediol), ethyldienolone (17α-ethyl-δ9-19-NT), norboletone (17α-ethyl-18-methyl-19-NT), propetandrol (17α-ethyl-19-NT 3β-propionate), and tetrahydrogestrinone (THG; 17α-ethyl-18-methyl-δ9,11-19-NT). The progestins allylestrenol (3-deketo-17α-allyl-19-NT) and lynestrenol (3-deketo-17α-ethynyl-19-NT) are also closely related to ethylestrenol, differing only by the C17α substitution.
== Research == Wadden’s research has focused on the behavioral and medical management of obesity. His early work on very low-calorie diets (VLCDs) included the first long-term trial of high-protein VLCDs, showing short-term efficacy but frequent weight regain, which underscored the need for long-term maintenance strategies. In the 1990s, he helped establish methods for evaluating commercial weight-loss programs, contributing to federal consumer-protection efforts. Beginning in the late 1990s, Wadden’s trials demonstrated that combining weight-loss medications with intensive lifestyle intervention (ILI) produced greater weight reduction than either approach alone, shaping clinical guidelines and drug trial designs. He also played a central role in research that supports the Centers for Medicare and Medicaid Services reimbursement of intensive behavioral therapy (IBT) for obesity. His studies showed that brief, protocol-driven IBT sessions delivered in primary care produced clinically meaningful weight loss. As a principal investigator on the NIH-funded Look AHEAD trial, Wadden helped show that ILI improved cardiometabolic risk factors, physical function, quality of life, and health-care costs in patients with type 2 diabetes, despite not reducing cardiovascular events. More recently, he has reported on glucagon-like peptide-1 (GLP-1) medications such as semaglutide and tirzepatide, which produce substantial weight loss and health benefits.
Chiral column chromatography is a variant of column chromatography that is employed for the separation of chiral compounds, i.e. enantiomers, in mixtures such as racemates or related compounds. The chiral stationary phase (CSP) is made of a support, usually silica based, on which a chiral reagent or a macromolecule with numerous chiral centers is bonded or immobilized. The chiral stationary phase can be prepared by attaching a chiral compound to the surface of an achiral support such as silica gel. For example, one class of the most commonly used chiral stationary phases both in liquid chromatography and supercritical fluid chromatography is based on oligosaccharides such as amylose, cellulose, or cyclodextrin (in particular with β-cyclodextrin, a seven sugar ring molecule) immobilized on silica gel. The principle can be also applied to the fabrication of Monolithic HPLC columns or Gas Chromatography columns. or Supercritical Fluid Chromatography columns.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。